Last reviewed · How we verify
Human Plasminogen
Activates plasminogen to break down blood clots
Activates plasminogen to break down blood clots Used for Acute ischemic stroke, Pulmonary embolism.
At a glance
| Generic name | Human Plasminogen |
|---|---|
| Sponsor | Kedrion S.p.A. |
| Drug class | Fibrinolytic agent |
| Target | Plasminogen |
| Modality | Biologic |
| Therapeutic area | Cardiovascular |
| Phase | Phase 2 |
Mechanism of action
Human plasminogen is a protein that plays a key role in the fibrinolytic system, which is responsible for breaking down blood clots. By activating plasminogen, this drug helps to dissolve blood clots and restore normal blood flow.
Approved indications
- Acute ischemic stroke
- Pulmonary embolism
Common side effects
- Hemorrhage
Key clinical trials
- Neuronavigation-assisted Stereotactic Minimally Invasive Puncture With Tenecteplase for Acute Lobar Intracerebral Hemorrhage (PHASE3)
- suPAR Michigan M2C2 Heterogeneity Validation Cohort Study
- Tenecteplase Before Interhospital Transfer for EVT in Acute Anterior Circulation LVO at 4.5-24 Hours (PHASE3)
- Precision Reperfusion Therapy for Disabling Minor Stroke With Large Vessel Occlusion Beyond Time Window (PHASE3)
- A Study to Test if Tenecteplase Helps People to Recover From an Acute Stroke When Given More Than 4.5 Hours After the Person Was Last Seen Well (PHASE3)
- Unknown Time of Onset Stroke RePerfusIon Without Advanced Imaging (PHASE3)
- Intravenous Tenecteplase in Very Old Patients With Acute Ischemic Stroke
- Reperfusion Completion Via Local Arterial Infusion of Tenecteplase After Incomplete Mechanical Thrombectomy (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Human Plasminogen CI brief — competitive landscape report
- Human Plasminogen updates RSS · CI watch RSS
- Kedrion S.p.A. portfolio CI